![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Court Overturns J&J Risperdal Verdict in California
Court Overturns J&J Risperdal Verdict in California
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/gavel_with_shadow.jpg?t=1435080640&width=430)
January 10, 2018
A California appeals court overturned a $5.6 million Risperdal verdict against Johnson & Johnson’s pharmaceutical division, Janssen.
After Leo Liu, a participant in a 2009 clinical study for Janssen’s drug Risperdal, died of cardiac arrest five days after enrollment, his parents sued the company. In 2015, a Los Angeles County Superior Court found the pharmaceutical giant responsible for the man’s death and awarded Liu’s parents $8 million – which included $2.4 million from Liu’s psychiatrist.
The appeals court, however, overturned the verdict and ruled that the company did not “owe the deceased a duty of care for a preexisting heart condition,” citing insufficient evidence linking the death to the medicine.
Upcoming Events
-
21Oct